Elena Vasil’evna Proskurnina – Ph.D. (Chem.), Associate Professor, Department of Medical Biophysics, Faculty of Funda-mental Medicine, Lomonosov Moscow State University
Galina Anatol’evna Dudina – Ph.D. (Med.), Head of the Department of Oncohematology, Loginov Moscow Clinical Scientific Center
Madina Magamedovna Sozarukova – Ph.D. (Biol.), Department of Biochemistry of Free-radical Processes, Myasnikov Institute of Clinical Cardiology
Lyudmila Robertovna Orlova – Physician of the City Clinic No. 191 of the Moscow Healthcare Department, Moscow
Yulia Alexandrovna Filippova – Student, Faculty of Fundamental Medicine, Lomonosov Moscow State University
Maya Andreevna Shestakova – Student, Pirogov Russian National Research Medical University
Aleksandr Vasil’evich Pivnik – Dr. Sc. (Med.), Professor, Head of the Scientific Department of Oncohematology and Secondary Immunodeficiency Diseases, Loginov Moscow Clinical Scientific Center
To evaluate the radical-producing function of neutrophils, the method of luminol-enhanced chemiluminescence with double-step activation (4β-phorbol-12-myristate-13 acetate followed by N-formyl-methionyl-leucyl-phenylalanine) was used. The activation coefficients for luminol-dependent chemiluminescencewere calculated as analytical parameters for the following groups of patients: 1) almost healthy donors, 2) patients with myelodysplastic syndrome (MDS), low risk, 3) MDS, intermediate 1 risk, 4) MDS, intermediate 2 risk, 5) MDS, high risk, in including patients with transformation into acute myeloid leukemia. These parameters were also calculated for patients before and after blood transfusion. It is shown that as the disease progresses, the activation coefficient decreases. Thus, this parameter of the radical-producing function of neutrophils can serve as a diagnostic and prognostic indicator for assessing the severity of the disease and the selection of the protocol of blood transfusion therapy.
- Savchenko V.G. (Ed.) System therapy of blooddis¬eases. M.: Praktika. 2012.
- Parovichnikova E.N., Pimenova M.A., Kokhno A.V., Savchenko V.G. Chromosomal abnormali¬ties in hematopoietic and stromal progenitor cells in myelodysplastic syndrome // Gemato-logiyaITransfuziologiya 2003. V. 58. № 4. P. 33–10.
- Gill H., Leung A.Y., Kwong Y.L. Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy // Int.J.Mol.Sci. 2016. V. 17. № 4. P. 440.
- Kennedy J.A., Ebert B.L. Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome // J.Clin.Oncology. 2017. V. 35. № 9. P. 968–974.
- Dexheimer G.M., Alves J., Reckziegel L., Lazzaretti G., Abujamra A.L. DNA Methylation Events as Markers for Diagnosis and Management of Acute Myeloid Leukemia and Myelodysplastic Syndrome // Disease Markers. 2017. V. 2017. P. 5472893.
- Bhatt G., Blum W.,Making the most of hypomethylating agents in myelodysplastic syndrome // Curr.Opinion Hematol. 2017. V. 24. № 2. P. 79–88.
- Sperling A.S., Gibson C.J., Ebert B.L. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia // Nature Rev. Cancer. 2017. V. 17. № 1. P. 5–19.
- Shah J., Kurtin S.E., Arnold L., Lindroos-Kolqvist P., Tinsley S. Management of transfusion-related iron overload in patients with myelodysplastic syndromes // Clin.J. Oncology Nursing. 2012. V. 16 Suppl. P. 37–46.
- Zeidan A.M., Pullarkat V.A., Komrokji R.S. Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome // Crit.Rev.Oncol/Hematol. 2017. V. 117. P. 57–66.
- Obraztsov I.V., Godkov M.A., Polimova A.M., Demin E.M., Proskurnina E.V., Vladimirov Yu.A. Evaluation of the functional activity of whole blood neutrophils by a two-step stimulation method: a new approach to chemiluminescence analysis // Rossiisky Immunologihesky Zhurnal.2015. V. 9. № 4. P. 418–425.
- Fehrman I., Ringden O. Lymphocytes from multitransfused uremic patients have poor MLC reactivity // Tissue antigens. 1981. V. 17. P. 386–395.